/ Unknown statusPhase 2/3 An Open-Label, Dose Escalation and Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Tolerability of Sepofarsen in Pediatric Subjects <8 Years of Age with Leber Congenital Amaurosis Type 10 (LCA10) due to the c.2991 +1655A>G (p.Cys998X) mutation
100 Clinical Results associated with ProQR Therapeutics IV BV
0 Patents (Medical) associated with ProQR Therapeutics IV BV
100 Deals associated with ProQR Therapeutics IV BV
100 Translational Medicine associated with ProQR Therapeutics IV BV